111 earnings date
Want to see YI full AI Analyst Report?
111 (YI) Q4 2024 Earnings Report
YI Q4 2024 EPS Results
- Actual EPS
- -$0.03
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -$0.51
YI Q4 2024 Revenue Results
- Actual Revenue
- $535.22M
- Expected Revenue
- $590.08M
- Beat/Miss
- Missed by -$54.86M
- YoY Revenue Growth
- -5.82%
Earnings Announcement Details
- Quarter
- Q4 2024
- Date
- 03/20/2025
- Time
- Before Open
- Conference Call
- Thursday, March 20, 2025
111's next earnings date is estimated for November 26, 2026, based on past reporting schedules.
Q4 2024 Earnings Call Audio
Q4 2024 Earnings Slide Deck
Q4 2024 Earnings Call Summary
The earnings call demonstrates significant achievements in operational profitability and cost reduction despite challenging macroeconomic conditions and regulatory changes. The company's advancements in technology and supply chain expansion position it well for future growth, though market and competitive pressures remain.
During the conference call held on March 20, 2025, the management of 111 provided insights into their fiscal year 2024 performance and future outlook. Despite macroeconomic challenges and healthcare reforms impacting the industry, 111 achieved its first-ever operational profitability and positive operating cash flow. The company reduced operating expenses by 31% year-over-year, bringing them down to 5.7% of revenues. Key financial highlights included a yearly profit from operations of RMB2.1 million, a turnaround from a RMB350.1 million operational loss in 2023, and a non-GAAP income from operations of RMB22.3 million. The company also highlighted advancements in technology and supply chain infrastructure, such as their decentralized inventory network and AI-driven demand forecasting, which significantly improved operational efficiency. Looking ahead, 111 plans to leverage AI and digital transformation to enhance customer engagement and operational efficiency, aiming to capitalize on China's evolving healthcare market and structural trends like the aging population and healthcare transparency reforms.
- First Ever Operational Profitability111 achieved its first ever operational profitability and positive operating cash flow in 2024, marking a significant milestone in the company's history.
- Reduction in Operating ExpensesTotal operating expenses decreased by 50.1% to RMB209.8 million in Q4 and by 31% for the full year, highlighting significant improvements in operational efficiency.
- Advanced AI and Digital CapabilitiesThe company integrated leading technologies across operations, improving efficiency with AI-driven solutions and a fully digitized operating system.
- Expansion of Fulfillment Centers111 expanded its supply chain infrastructure with seven new fulfillment centers, increasing delivery efficiency and reducing costs.
- Market Leadership and Industry Recognition111 received multiple industry recognitions, including being named the most valuable healthcare and pharmaceutical company for investment.
YI Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 26, 2026 | 2026 (Q3) | ―- | -0.21 | ― | ― |
| Sep 17, 2026 | 2026 (Q2) | ―-0.66 | -0.33 | -100.00% (-0.33) | |
| Jun 04, 2026 | 2026 (Q1) | ―- | -0.3 | ― | |
| Apr 09, 2026 | 2025 (Q4) | ―-0.63 | -0.3 | -110.00% (-0.33) | |
| Dec 17, 2025 | 2025 (Q3) | ―-0.21 | -0.3 | 30.00% (+0.09) | |
| Sep 17, 2025 | 2025 (Q2) | ―-0.33 | -0.24 | -37.50% (-0.09) | |
| Jun 19, 2025 | 2025 (Q1) | ―-0.30 | -0.03 | -792.86% (-0.26) | |
| Mar 20, 2025 | 2024 (Q4) | ―-0.03 | -0.51 | 93.58% (+0.48) | |
| Nov 27, 2024 | 2024 (Q3) | ―-0.30 | -0.23 | -31.32% (-0.07) | |
| Aug 29, 2024 | 2024 (Q2) | ―-0.24 | -1.01 | 76.47% (+0.78) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


